FIELD: medicine, pharmaceutics.
SUBSTANCE: presented invention refers to immunology. There are presented a monoclonal antibody binding to at least three CC-chemokines, such as RANTES/CCL5, MIP-1α/CCL3 or MIP-1β/CCL4, and its antigen-binding fragment. There are also disclosed a hybridoma cell lines producing the antibodies according to the invention, a composition containing the antibody according to the invention or its antigen-binding fragment, and a method of treating a disease, disorder or condition mediated by one or more CC-chemokines.
EFFECT: invention can find further application in regulation of various inflammatory and autoimmune diseases.
44 cl, 13 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-1 BINDING PROTEINS | 2011 |
|
RU2615173C2 |
| ANTIBODY AGAINST CCR5 | 2003 |
|
RU2322454C2 |
| TREATING OSTEOARTHRITIS AND PAIN | 2012 |
|
RU2563830C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
| IL-1 ALPHA AND BETA BISPECIFIC IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION | 2011 |
|
RU2627171C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
| INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
| MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
